Tolerance of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with self-reported statin intolerance

ER Davidson, MJ Snider, K Bartsch… - Journal of …, 2020 - journals.sagepub.com
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been
shown to lower atherogenic lipid markers in patients with statin intolerance; however …
被引用次数：7 相关文章

Tolerance of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors in Patients With Self-Reported Statin Intolerance

ER Davidson, MJ Snider, K Bartsch… - Journal of …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been
shown to lower atherogenic lipid markers in patients with statin intolerance; however …

Tolerance of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors in Patients With Self-Reported Statin Intolerance.

ER Davidson, MJ Snider, K Bartsch… - Journal of Pharmacy …, 2018 - europepmc.org
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been
shown to lower atherogenic lipid markers in patients with statin intolerance; however …

Tolerance of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors in Patients With Self-Reported Statin Intolerance.

ER Davidson, MJ Snider, K Bartsch… - Journal of …, 2020 - search.ebscohost.com
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been
shown to lower atherogenic lipid markers in patients with statin intolerance; however …

Tolerance of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors in Patients With Self-Reported Statin Intolerance

ER Davidson, MJ Snider, K Bartsch, A Hirsch… - Journal of Pharmacy …, 2018 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> Proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to lower atherogenic lipid …

Tolerance of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors in Patients With Self-Reported Statin Intolerance

ER Davidson, MJ Snider, K Bartsch… - Journal of …, 2020 - ohiostate.elsevierpure.com
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been
shown to lower atherogenic lipid markers in patients with statin intolerance; however …